Evidence map›Paper›PMID 30114914›Full record

ArticleMolecular pharmaceutics2018

Comparing Multiple Machine Learning Algorithms and Metrics for Estrogen Receptor Binding Prediction.

Daniel P Russo, Kimberley M Zorn, Alex M Clark, Hao Zhu, Sean Ekins

Abstract read
In one paragraph

Article in Molecular pharmaceutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
79citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

79 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Staying Ahead of the Game: How SARS-CoV-2 has Accelerated the Application of Machine Learning in Pandemic Management.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2023
    Review
  20. Article

19 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Daniel P RussoCollaborations Pharmaceuticals, Inc. , 840 Main Campus Drive, Lab 3510 , Raleigh , North Carolina 27606 , United States.
Kimberley M ZornCollaborations Pharmaceuticals, Inc. , 840 Main Campus Drive, Lab 3510 , Raleigh , North Carolina 27606 , United States.
Alex M ClarkMolecular Materials Informatics, Inc. , Montreal , Quebec H3J 2S1 , Canada.
Hao ZhuThe Rutgers Center for Computational and Integrative Biology , Camden , New Jersey 08102 , United States.
Sean EkinsCollaborations Pharmaceuticals, Inc. , 840 Main Campus Drive, Lab 3510 , Raleigh , North Carolina 27606 , United States.ORCID 0000-0002-5691-5790

Funding

Centralized assay datasets for modelling support of small drug discovery organizationsR44GM122196 · NIGMS · COLLABORATIONS PHARMACEUTICALS, INC. · PI EKINS, SEAN · 2018 to 2022
$3.3M
Predictive Computational Acute Toxicity Modeling by Profiling Chemicals With PublR15ES023148 · NIEHS · RUTGERS THE STATE UNIV OF NJ CAMDEN · PI ZHU, HAO · 2013 to 2018
$941k
Centralized assay datasets for modelling support of small drug discovery organizationsR43GM122196 · NIGMS · COLLABORATIONS PHARMACEUTICALS, INC. · PI EKINS, SEAN · 2017 to 2017
$150k
NIEHS NIH HHS R15 ES023148NIGMS NIH HHS R43 GM122196NIGMS NIH HHS R44 GM122196
6 · The paper itself

Abstract

Many chemicals that disrupt endocrine function have been linked to a variety of adverse biological outcomes. However, screening for endocrine disruption using in vitro or in vivo approaches is costly and time-consuming. Computational methods, e.g., quantitative structure-activity relationship models, have become more reliable due to bigger training sets, increased computing power, and advanced machine learning algorithms, such as multilayered artificial neural networks. Machine learning models can be used to predict compounds for endocrine disrupting capabilities, such as binding to the estrogen receptor (ER), and allow for prioritization and further testing. In this work, an exhaustive comparison of multiple machine learning algorithms, chemical spaces, and evaluation metrics for ER binding was performed on public data sets curated using in-house cheminformatics software (Assay Central). Chemical features utilized in modeling consisted of binary fingerprints (ECFP6, FCFP6, ToxPrint, or MACCS keys) and continuous molecular descriptors from RDKit. Each feature set was subjected to classic machine learning algorithms (Bernoulli Naive Bayes, AdaBoost Decision Tree, Random Forest, Support Vector Machine) and Deep Neural Networks (DNN). Models were evaluated using a variety of metrics: recall, precision, F1-score, accuracy, area under the receiver operating characteristic curve, Cohen's Kappa, and Matthews correlation coefficient. For predicting compounds within the training set, DNN has an accuracy higher than that of other methods; however, in 5-fold cross validation and external test set predictions, DNN and most classic machine learning models perform similarly regardless of the data set or molecular descriptors used. We have also used the rank normalized scores as a performance-criteria for each machine learning method, and Random Forest performed best on the validation set when ranked by metric or by data sets. These results suggest classic machine learning algorithms may be sufficient to develop high quality predictive models of ER activity.

Indexed as

Machine LearningAlgorithmsAnimalsBayes TheoremHumansProtein BindingReceptors, EstrogenSoftwareSupport Vector MachineReceptors, EstrogenBayesiandeep learningestrogen receptormachine learningsupport vector machine

Identifiers

PMID30114914
PMCPMC6181119

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.